Abstract
Lower hemoglobin is associated with cognitive impairment and Alzheimer's disease (AD). Since brain iron homeostasis is perturbed in AD, we investigated whether this is peripherally reflected in the hematological and related blood chemistry values from the Australian Imaging Biomarker and Lifestyle (AIBL) study (a community-based, cross-sectional cohort comprising 768 healthy controls (HC), 133 participants with mild cognitive impairment (MCI) and 211 participants with AD). We found that individuals with AD had significantly lower hemoglobin, mean cell hemoglobin concentrations, packed cell volume and higher erythrocyte sedimentation rates (adjusted for age, gender, APOE-ɛ4 and site). In AD, plasma iron, transferrin, transferrin saturation and red cell folate levels exhibited a significant distortion of their customary relationship to hemoglobin levels. There was a strong association between anemia and AD (adjusted odds ratio (OR)=2.43, confidence interval (CI) (1.31, 4.54)). Moreover, AD emerged as a strong risk factor for anemia on step-down regression, even when controlling for all other available explanations for anemia (adjusted OR=3.41, 95% CI (1.68, 6.92)). These data indicated that AD is complicated by anemia, which may itself contribute to cognitive decline.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Raman spectroscopy and multivariate analysis as potential tool to follow Alzheimer’s disease progression
Analytical and Bioanalytical Chemistry Open Access 19 May 2022
-
Analysis of plasma proteins using 2D gels and novel fluorescent probes: in search of blood based biomarkers for Alzheimer’s disease
Proteome Science Open Access 26 January 2022
-
Anaemia and cerebrospinal fluid biomarkers of Alzheimer’s pathology in cognitively normal elders: the CABLE study
BMC Neurology Open Access 19 November 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout


References
Prince M, Jackson J . World Alzheimer report 2009. Alzheimer's disease International, London, UK; www.alz.co.uk/research/files/WorldAlzheimerReport.pdf.
Atti AR, Palmer K, Volpato S, Zuliani G, Winblad B, Fratiglioni L . Anaemia increases the risk of dementia in cognitively intact elderly. Neurobiol Aging 2006; 27: 278–284.
Van Rensbergen G, Nawrot T . Medical conditions of nursing home admissions. BMC Geriatr 2010; 10: 46.
Shah RC, Wilson RS, Tang Y, Dong X, Murray A, Bennett DA . Relation of hemoglobin to level of cognitive function in older persons. Neuroepidemiology 2009; 32: 40–46.
Deal JA, Carlson MC, Xue Q-L, Fried LP . Chaves PHM. Anemia and 9-year domain-specific cognitive decline in community-dwelling older women: The Women's Health and Aging Study II. J Am Geriatr Soc 2009; 57: 1604–1611.
Denny SD, Kuchibhatla MN, Cohen HJ . Impact of anemia on mortality, cognition, and function in community-dwelling elderly. Am J Med 2006; 119: 327–334.
Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 2012; 69: 1318–1325.
Shah RC, Buchman AS, Wilson RS, Leurgans SE, Bennett DA . Hemoglobin level in older persons and incident Alzheimer disease: prospective cohort analysis. Neurology 2011; 77: 219–226.
Ferrer I, Gomez A, Carmona M, Huesa G, Porta S, Riera-Codina M et al. Neuronal hemoglobin is reduced in Alzheimer's disease, Argyrophilic Grain disease, Parkinson's disease, and dementia with Lewy bodies. J Alzheimers Dis 2011; 23: 537–550.
Smith MA, Harris PL, Sayre LM, Perry G . Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997; 94: 9866–9868.
Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K et al. Iron-export ferroxidase activity of beta- amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 2010; 142: 857–867.
Perry RT, Gearhart DA, Wiener HW, Harrell LE, Barton JC, Kutlar A et al. Hemoglobin binding to A beta and HBG2 SNP association suggest a role in Alzheimer's disease. Neurobiol Aging 2008; 29: 185–193.
Kauwe JSK, Bertelsen S, Mayo K, Cruchaga C, Abraham R, Hollingworth P et al. Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 955–959.
Lehmann DJ, Schuur M, Warden DR, Hammond N, Belbin O, Kölsch H et al. Transferrin and HFE genes interact in Alzheimer's disease risk: the Epistasis Project. Neurobiol Aging 2012; 33: 202.e1–202.e13.
Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 2012; 18: 291–295.
Cho HH, Cahill CM, Vanderburg CR, Scherzer CR, Wang B, Huang X et al. Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. J Biol Chem 2010; 285: 31217–31232.
Ellis K, Bush A, Darby D, De Fazio D, Foster J, Hudson P et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 2009; 21: 672–687.
Box G, Cox D . An analysis of transformations. J R Stat Soc Ser B 1964; 26: 211–243.
Benjamini Y, Hochberg Y . Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995; 57: 289–300.
World Health Organization. Iron Deficiency Anaemia: Assessment, Prevention, and Control: A Guide For Programme Managers. UNICEF United Nations University: WHO, Geneva, Switzerland, 2001.
Beard CM, Kokmen E, O'Brien PC, Anía BJ, Melton LJ . Risk of Alzheimer's disease among elderly patients with anemia: population-based investigations in Olmsted County, Minnesota. Ann Epidemiol 1997; 7: 219–224.
Maccio A, Madeddu C, Massa D, Mudu MC, Lusso MR, Gramignano G et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood 2005; 106: 362–367.
Ajmani RS, Metter EJ, Jaykumar R, Ingram DK, Spangler EL, Abugo OO et al. Hemodynamic changes during aging associated with cerebral blood flow and impaired cognitive function. Neurobiol Aging 2000; 21: 257–269.
De Franceschi L, Olivieri O, Corrocher R . Erythrocyte aging in neurodegenerative disorders. Cell Mol Biol 2004; 50: 179–185.
Mohanty JG, Eckley DM, Williamson JD, Launer LJ, Rifkind JM . Do red blood cell-beta-amyloid interactions alter oxygen delivery in Alzheimer's disease? Adv Exp Med Biol 2008; 614: 29–35.
Mohanty JG, Shukla HD, Williamson JD, Launer LJ, Saxena S, Rifkind JM . Alterations in the red blood cell membrane proteome in Alzheimer's subjects reflect disease-related changes and provide insight into altered cell morphology. Proteome Sci 2010; 8: 11.
Amos R, Dawson D, Fish D, Lemming R, Linnell J . Guidelines on the investigation and diagnosis of cobalamin and folate deficiencies. A publication of the British Committee for Standards in Haematology. BCSH General Haematology Test Force. Clin Lab Haematol 1994; 16: 101–115.
Faux NG, Ellis KA, Porter L, Fowler CJ, Laws SM, Martins RN et al. Homocysteine, vitamin B12, and folic acid levels in Alzheimer's disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study. J Alzheimers Dis 2011; 27: 909–922.
Naj AC, Beecham GW, Martin ER, Gallins PJ, Powell EH, Konidari I et al. Dementia revealed: novel chromosome 6 locus for late-onset Alzheimer disease provides genetic evidence for folate-pathway abnormalities. PLoS Genet 2010; 6: 9e1001130.
Suh JR, Oppenheim EW, Girgis S, Stover PJ . Purification and properties of a folate-catabolizing enzyme. J Biol Chem 2000; 275: 35646–35655.
Zhang R, Barker L, Pinchev D, Marshall J, Rasamoelisolo M, Smith C et al. Mining biomarkers in human sera using proteomic tools. Proteomics 2004; 4: 244–256.
Dyrks T, Dyrks E, Hartmann T, Masters C, Beyreuther K . Amyloidogenicity of beta A4 and beta A4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J Biol Chem 1992; 267: 18210–18217.
Chuang JY, Lee CW, Shih YH, Yang T, Yu L, Kuo YM . Interactions between amyloid-beta and hemoglobin: implications for amyloid plaque formation in Alzheimer's disease. PLoS One 2012; 7: e33120.
Rogers J, Li R, Mastroeni D, Grover A, Leonard B, Ahern G et al. Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol Aging 2006; 27: 1733–1739.
Villemagne VL, Perez KA, Pike KE, Kok WM, Rowe CC, White AR et al. Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease. J Neurosci 2010; 30: 6315–6322.
Jayakumar R, Kusiak JW, Chrest FJ, Demehin AA, Murali J, Wersto RP et al. Red cell perturbations by amyloid beta-protein. Biochim Biophys Acta 2003; 1622: 20–28.
Acknowledgements
Core funding for the study was provided by CSIRO, which was supplemented by in-kind contributions from the study partners (see http://www.aibl.csiro.au/). The research was also supported by the Science Industry and Endowment Fund (see www.sief.org.au), the Cooperative Research Center for Mental Health, and the National Health and Medical Research Council (NHMRC) via the Dementia Collaborative Research Centres program (DCRC2). The Florey Institute acknowledges the funding support from the Victorian Government’s Operational Infrastructure Support program. NGF is supported by a NHMRC training fellowship. AIB is supported by NHMRC Australia Fellowship. Pfizer International has contributed financial support to assist with analysis of blood samples and to further the AIBL research program. The McCusker Foundation has contributed financial and in-kind support to AIBL. Alzheimer’s Australia (Victoria and Western Australia) assisted with promotion of the study and the screening of telephone calls from volunteers. The AIBL team thanks the following clinicians who referred patients with AD and/or MCI to the study: Associate Professor Brian Chambers, Professor Edmond Chiu, Dr Roger Clarnette, Associate Professor David Darby, Dr Mary Davison, Dr John Drago, Dr Peter Drysdale, Dr Jacqui Gilbert, Dr Kwang Lim, Professor Nicola Lautenschlager, Dr Dina LoGiudice, Dr Peter McCardle, Dr Steve McFarlane, Dr Alastair Mander, Dr John Merory, Professor Daniel O’Connor, Dr Ron Scholes, Dr Mathew Samuel, Dr Darshan Trivedi, Dr Peter Panegyres and Associate Professor Michael Woodward.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
AIB and CLM are shareholders in Prana Biotechnology Limited. AIB is a shareholder in Cogstate Limited and Mesoblast Limited.
Additional information
Supplementary Information accompanies the paper on the Molecular Psychiatry website
Supplementary information
PowerPoint slides
Rights and permissions
About this article
Cite this article
Faux, N., Rembach, A., Wiley, J. et al. An anemia of Alzheimer's disease. Mol Psychiatry 19, 1227–1234 (2014). https://doi.org/10.1038/mp.2013.178
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/mp.2013.178
Keywords
- alzheimer's disease
- anemia
- folate
- hematology
- hemoglobin
- iron
This article is cited by
-
Analysis of plasma proteins using 2D gels and novel fluorescent probes: in search of blood based biomarkers for Alzheimer’s disease
Proteome Science (2022)
-
Raman spectroscopy and multivariate analysis as potential tool to follow Alzheimer’s disease progression
Analytical and Bioanalytical Chemistry (2022)
-
Anaemia and cerebrospinal fluid biomarkers of Alzheimer’s pathology in cognitively normal elders: the CABLE study
BMC Neurology (2021)
-
Change in the plasma proteome associated with canine cognitive dysfunction syndrome (CCDS) in Thailand
BMC Veterinary Research (2021)
-
Deferiprone Treatment in Aged Transgenic Tau Mice Improves Y-Maze Performance and Alters Tau Pathology
Neurotherapeutics (2021)